 Precigen Incs NASDAQ: PGEN subsidiary Precigen ActoBio announced topline results from the Phase 1b2a study evaluating AG019 ActoBiotics to treat recent-onset type 1 diabetes T1D. Results were presented at the Federation of Clinical Immunology Societies 2021. 